Publications (200) ARTURO FERNÁNDEZ-CRUZ PÉREZ publications

2015

  1. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes

    New England Journal of Medicine, Vol. 373, Núm. 22, pp. 2117-2128

2014

  1. Diagnosis of subclinical atherosclerosis in HIV-infected patients: Higher accuracy of the D:A:D risk equation over Framingham and SCORE algorithms

    European Journal of Preventive Cardiology, Vol. 21, Núm. 6, pp. 739-748

  2. The CD4: CD8 ratio is associated with markers of age-associated disease in virally suppressed HIV-infected patients with immunological recovery

    HIV Medicine, Vol. 15, Núm. 1, pp. 40-49

2013

  1. Authors reply: Association of HIV-infection and antiretroviral therapy with levels of endothelial progenitor cells and subclinical atherosclerosis

    Journal of Acquired Immune Deficiency Syndromes

  2. Coinfección por VIH/VHB: estrategias terapéuticas y control serológico

    Revista Clinica Espanola, Vol. 213, Núm. 6, pp. 285-290

  3. Differential clinical characteristics and prognosis of intraventricular conduction defects in patients with chronic heart failure

    European Journal of Heart Failure, Vol. 15, Núm. 8, pp. 877-884

  4. Eplerenone enhances cardioprotective effects of standard heart failure therapy through matricellular proteins in hypertensive heart failure

    Journal of Hypertension, Vol. 31, Núm. 11, pp. 2309-2319

  5. Hipertensión por hiperaldosteronismo: más lesión cardiaca, mayor riesgo cardiovascular

    Revista Espanola de Cardiologia, Vol. 66, Núm. 1, pp. 47-52

2012

  1. Association of HIV-infection and antiretroviral therapy with levels of endothelial progenitor cells and subclinical atherosclerosis

    Journal of Acquired Immune Deficiency Syndromes

  2. Circulating endothelial progenitor cells are reduced in rat oxygen-induced retinopathy despite a retinal SDF-1/CXCR4 and VEGF proangiogenic response

    Life Sciences, Vol. 91, Núm. 7-8, pp. 264-270

  3. Ezetimibe inhibits PMA-induced monocyte/macrophage differentiation by altering microRNA expression: A novel anti-atherosclerotic mechanism

    Pharmacological Research, Vol. 66, Núm. 6, pp. 536-543

  4. Factores clínicos y biomarcadores asociados a lesión vascular subclínica en la infección por el virus de la inmunodeficiencia humana

    Medicina Clinica, Vol. 139, Núm. 6, pp. 231-237

  5. Incipient renal impairment as a predictor of subclinical atherosclerosis in HIV-infected patients

    Journal of Acquired Immune Deficiency Syndromes, Vol. 59, Núm. 2, pp. 141-148

2011

  1. Ezetimibe inhibe la adhesión y la migración de monocitos a través de la ruta de las proteincinasas activadas extracelularmente (p44/p42ERK1/2

    Clínica e investigación en arteriosclerosis, Vol. 23, Núm. 4, pp. 160-167

  2. Ezetimibe inhibe la adhesión y la migración de monocitos a travésde la ruta de las proteincinasas activadas extracelularmente(p44/p42ERK1/2

    Clinica e Investigacion en Arteriosclerosis, Vol. 23, Núm. 4, pp. 160-167

2010

  1. Influence of metabolic syndrome on risk stratification in hypertensive patients: Differences between 2003 and 2007 ESH-ESC guidelines

    Therapeutic Advances in Cardiovascular Disease, Vol. 4, Núm. 2, pp. 97-103

  2. Local non-esterified fatty acids correlate with inflammation in atheroma plaques of patients with type 2 diabetes

    Diabetes, Vol. 59, Núm. 6, pp. 1292-1301

  3. Management of resistant arterial hypertension: Role of spironolactone versus double blockade of the renin-angiotensin-aldosterone system

    Journal of Hypertension, Vol. 28, Núm. 11, pp. 2329-2335

  4. Rosuvastatin added to standard heart failure therapy improves cardiac remodelling in heart failure rats with preserved ejection fraction

    European Journal of Heart Failure, Vol. 12, Núm. 9, pp. 903-912

2009

  1. A prospective study of the management of non-massive pulmonary embolism in the home

    European Journal of Internal Medicine, Vol. 20, Núm. 6, pp. 598-600